SMS Pharmaceuticals · NSE: SMSPHARMA · BSE: 532815
Q2 FY26 results · Jul–Sep 2025
SMS Pharmaceuticals reported revenue from operations of ₹242.43 crore (up 23.2% from Q2 FY25) and net profit of ₹25.31 crore (up 79.5% from Q2 FY25) for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 242.43 | 196.75 | +23.2% | 196.05 | +23.7% |
| Other income | 1.43 | 1.30 | +9.9% | 0.59 | +141.8% |
| Total income | 243.86 | 198.05 | +23.1% | 196.64 | +24.0% |
| Profit before share of associates & JVs and tax | 34.04 | 19.54 | +74.2% | 24.37 | +39.7% |
| Share of profit/(loss) of associates & JVs | 0.18 | 0.24 | 1.78 | ||
| Net profit for the period | 25.31 | 14.10 | +79.5% | 20.49 | +23.5% |
| EPS, basic (₹) | 2.84 | 1.69 | not comparable | 2.31 | +22.9% |
| Net margin (%) | 10.4 | 7.2 | 10.5 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 242.43 | 196.75 | +23.2% | 196.05 | +23.7% |
| Other income | 1.43 | 1.30 | +9.9% | 0.59 | +141.8% |
| Total income | 243.86 | 198.05 | +23.1% | 196.64 | +24.0% |
| Profit before tax | 34.06 | 19.94 | +70.8% | 23.86 | +42.7% |
| Net profit for the period | 25.14 | 14.26 | +76.3% | 18.21 | +38.1% |
| EPS, basic (₹) | 2.82 | 1.68 | not comparable | 2.05 | +37.6% |
| Net margin (%) | 10.4 | 7.2 | 9.3 |
Consolidated
- Filed with BSE
- 08 Nov 2025, 17:13 IST
- Board meeting
- 08 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 08 Nov 2025, 17:13 IST
- Board meeting
- 08 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE